Amgen Inc. (NASDAQ:AMGN) Shares Acquired by MONECO Advisors LLC

MONECO Advisors LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 44.6% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,711 shares of the medical research company’s stock after purchasing an additional 1,145 shares during the period. MONECO Advisors LLC’s holdings in Amgen were worth $967,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Capital Performance Advisors LLP acquired a new position in shares of Amgen in the third quarter worth $25,000. Centricity Wealth Management LLC purchased a new position in Amgen in the fourth quarter valued at $25,000. Legacy Investment Solutions LLC purchased a new position in Amgen in the third quarter valued at $29,000. Heck Capital Advisors LLC acquired a new position in Amgen during the 4th quarter worth $36,000. Finally, PrairieView Partners LLC increased its holdings in Amgen by 118.3% during the 4th quarter. PrairieView Partners LLC now owns 179 shares of the medical research company’s stock worth $46,000 after purchasing an additional 97 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Up 1.7 %

Shares of NASDAQ:AMGN opened at $303.01 on Monday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The stock has a market cap of $162.78 billion, a P/E ratio of 40.13, a P/E/G ratio of 2.58 and a beta of 0.56. The firm has a fifty day moving average price of $276.27 and a 200 day moving average price of $300.31.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Sell-side analysts predict that Amgen Inc. will post 20.6 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.14%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is 126.09%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on AMGN. Wolfe Research began coverage on Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. UBS Group reiterated a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Truist Financial decreased their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research report on Wednesday, January 8th. Finally, Piper Sandler increased their target price on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $314.09.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Murdo Gordon sold 8,771 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the transaction, the executive vice president now directly owns 44,186 shares in the company, valued at $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.